We have observed
2 EP applications
Xavier Vallvé Sánchez
has served for within the last five+ years.
(We consider all applications which have an EP A1 or A2 publication dated after June 15, 2013).
Please note, that we only count EP applications,
in which the name of the patent attorney is explicitly mentioned as representative.
These EP applications are:
Neuroprotective multi-target directed drugs
PEPTIDE FOR USE IN THE TREATMENT OF DISEASE CAUSED BY CLOSTRIDIUM NEUROTOXINS